<DOC>
	<DOC>NCT02168426</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of Seprafilm and guardix in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm and guardix occurring within 30 days postoperatively.</brief_summary>
	<brief_title>Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Clinical diagnosis of GI cancer Operable Withdrew consent Pregnant Ascites Distant metastasis Liver dysfunction (serum total bilirubin &gt;2.0 mg/dL) Renal failure (serum creatinine &gt;1.5 mg/dL) A past history of small bowel obstruction.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>